(+)-3-(2,4-dimethyl-9-{4-[(S)-2-oxo-2-(4-propylpiperazin-1-yl)-1-(tetrahydro-2H-pyran-4-yl)ethyl]benzyl}9H-pyrido[2,3-b]indol-3-yl)propanoic acid | 629611-50-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (+)-3-(2,4-dimethyl-9-{4-[(S)-2-oxo-2-(4-propylpiperazin-1-yl)-1-(tetrahydro-2H-pyran-4-yl)ethyl]benzyl}9H-pyrido[2,3-b]indol-3-yl)propanoic acid
• 英文别名: (+)-3-(2,4-Dimethyl-9-{4-[(S)-2-oxo-2-(4-propylpiperazin-1-yl)-1-(tetrahydro-2H-pyran-4-yl)ethyl]benzyl}-9H-pyrido[2,3-b]indol-3-yl)propanoic acid；3-[2,4-dimethyl-9-[[4-[(1S)-1-(oxan-4-yl)-2-oxo-2-(4-propylpiperazin-1-yl)ethyl]phenyl]methyl]pyrido[2,3-b]indol-3-yl]propanoic acid
• CAS: 629611-50-3
• 化学式: C₃₇H₄₆N₄O₄
• 分子量: 610.797
• InChiKey: KFLFETVAKGGAEX-PGUFJCEWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  45
• 可旋转键数：
  10
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.49
• 拓扑面积：
  87.9
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  benzyl (+)-3-(2,4-dimethyl-9-{4-[(S)-2-oxo-2-(4-propylpiperazin-1-yl)-1-(tetrahydro-2H-pyran-4-yl)ethyl]benzyl}-9H-pyrido[2,3-b]indol-3-y)propanoate 在 palladium 10% on activated carbon 氢气 作用下， 以 四氢呋喃 为溶剂， 生成 (+)-3-(2,4-dimethyl-9-{4-[(S)-2-oxo-2-(4-propylpiperazin-1-yl)-1-(tetrahydro-2H-pyran-4-yl)ethyl]benzyl}9H-pyrido[2,3-b]indol-3-yl)propanoic acid
  参考文献：
  名称：

  Tetrahydropyran derivatives

  摘要：

  公开号：

  EP1367058B1

文献信息

• Novel phenyl-substituted imidazolidines, process for preparation thereof, medicaments comprising said compounds and use thereof
  申请人：JAEHNE Gerhard

  公开号：US20110178134A1

  公开（公告）日：2011-07-21

  The invention relates to compounds of formula (I) wherein the groups have stated meanings, and to their physiologically compatible salts. Said compounds are suitable, for example, as anti-obesity drugs and for treating cardiometabolic syndrome.

  本发明涉及具有所述意义的公式（I）的化合物，以及它们的生理相容性盐。所述化合物适用于例如作为抗肥胖药物和治疗心血管代谢综合征。
• AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES
  申请人：Petry Stefan

  公开号：US20130157941A1

  公开（公告）日：2013-06-20

  The present invention relates to azolopyridin-3-one derivatives of the general formula (I) with the meanings specified in the description, to their pharmaceutically usable salts and to their use as drug substances.

  本发明涉及通式（I）所示的咪唑吡啶-3-酮衍生物，其含义如描述中所指定的，以及它们的药用盐和作为药物物质的用途。
• Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof
  申请人：JAEHNE Gerhard

  公开号：US20110053947A1

  公开（公告）日：2011-03-03

  The invention relates to compounds of formula (I) wherein the groups R and R′, A, D, E, G, L, p and R1 to R10 have the stated meanings and to their physiologically compatible salts. Said compounds are suitable, for example, as anti-obesity drugs.

  本发明涉及具有公式（I）的化合物，其中R和R'、A、D、E、G、L、p以及R1至R10具有所述含义，以及它们的生理相容性盐。所述化合物例如可作为抗肥胖药物使用。
• Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use
  申请人：JAEHNE Gerhard

  公开号：US20090215728A1

  公开（公告）日：2009-08-27

  This invention relates to arylaminoaryl-alkyl-substituted imidazolidone-2,4-diones of formula (I) and also to their physiologically tolerated salts: Wherein R, R′, R1 to R10, A, D, E, G, L and p are as defined herein. The invention also relates to processes for preparing them, pharmaceutical compositions comprising them and their therapeutic use. The compounds are suitable, for example, as anti-obesity drugs and for treating cardiometabolic syndrome.

  这项发明涉及公式（I）中的芳基氨基芳基烷基取代的咪唑烷二酮及其生理耐受的盐： 其中R、R'、R1至R10、A、D、E、G、L和p如本文所定义。该发明还涉及制备它们的方法、包含它们的药物组合物以及它们的治疗用途。这些化合物适用于例如作为抗肥胖药物和治疗心脏代谢综合征。
• Novel aromatic fluoroglycoside derivatives, pharmaceuticals comprising said compounds and the use thereof
  申请人：FRICK Wendelin

  公开号：US20110059910A1

  公开（公告）日：2011-03-10

  The invention relates to substituted aromatic fluoroglycoside derivatives, and to the physiologically compatible salts and physiologically functional derivatives thereof. The invention also relates to methods of lowering blood sugar and the treatment of type I and type II diabetes.

  这项发明涉及取代芳香族氟糖苷衍生物，以及其生理兼容盐和生理功能衍生物。该发明还涉及降低血糖和治疗I型和II型糖尿病的方法。